News & Updates

The use of menopausal hormone therapy (MHT) can provide protection against psychosis relapse among women of menopausal age with schizophrenia or schizoaffective disorder (SSD), a study has shown.

In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Neurologic and psychiatric complications associated with influenza occurs rarely in the paediatric population, but such incidence can be severe and may even lead to hospitalization, suggests a study.

Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).

In the management of severe cancer pain, intravenous patient-controlled analgesia (PCA) with hydromorphone delivers superior pain control with greater patient satisfaction as compared with conventional oral morphine, according to the phase III open-label SYLT-021 study.

Patients with patent foramen ovale (PFO) closure have a greater risk of ischaemic stroke at 4 years than those in the general population, according to a study.